Mary L. (Nora) Disis (@DrNDisis) header
Mary L. (Nora) Disis (@DrNDisis) profile picture

Director, UW Medicine Cancer Vaccine Institute. Editor in Chief, JAMA Oncology. Research: vaccines for the prevention of cancer and cancer relapse.

University of Washington
Joined February 2015
Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)Photo by Mary L. (Nora) Disis (@DrNDisis)
CVI Director @DrNDisis, Exec Dir @kirandhillonphd & colleagues are at #SITC2022! Grad students & postdocs interested in an exciting career in cancer vaccines & tumor immunology, we want to meet you! Discovery, translation, and clinical trials under one roof. Email: [email protected]
8
We’re excited to share a new paper by CVI’s Dr. John Liao on a clinical trial for combination Pembrolizumab and low dose carboplatin in women with recurrent, platinum resistant ovarian cancer. Read more uwcvi.org/post/new-cvi-paper… #ovariancancerawarenessmonth #gyncsm #immunotherapy
4
2
4
Mary L. (Nora) Disis retweeted
👨‍⚕️👩‍⚕️ Drs. Sasha Stanton (@sestant29), Nora Disis (@DrNDisis), and fellow @UWCancerVaccine researchers found that candidate targets recovered from mouse #mammary tumor models are also immunogenic in human #BreastCancer. 📚 Abstact: go.nature.com/3y780Vb
3
1
13
Mary L. (Nora) Disis retweeted
5 immune response markers might predict #COVID19 patient outcomes & possibly become useful in candidate vaccine assessment, according to @ImmunityCP @CellCellPress study @ragoninstitute & @UWMedicine headed by Galit Alter & Helen Chu https://nitter.cf/t.co/2cnwu1MirL
13
25
Mary L. (Nora) Disis retweeted
In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCLC? Please amplify as needed in the comments. #LCSM
27%For EGFR mut'n alone
50%Broad testing (e.g., NGS)
23%None (waiting for OS)
344 votes • Final results
9
12
2
22
Mary L. (Nora) Disis retweeted
Thanks for my nicest colleagues! I am the best, because all of you! @UWCancerVaccine
We're so excited to announce that the CVI's Ying Liu successfully defended her PhD in Epidemiology ( @Vanderbilt ) today! Dr. Liu joined the CVI this past spring as our biostatistician! We're so happy to have her on our team! @DrNDisis @UWMedicine #womeninscience
2
6
Laura is an amazing scientist!
CVI’s Dr. Laura Riolobos is making a #vaccine for #liposarcoma, to help her friend & others with this rare #cancer. Read more: https://nitter.cf/t.co/QQv9f3U6vu @UWMedicine #SarcomaAwareness #CureSarcoma #Sarcoma #Research
2
7
Pembrolizumab After Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer ja.ma/2O5xGif New at @JAMA Onc-ablation of oligometastatic NSCLC followed by immune checkpoint: OS at 12 mo-90%. Novel and promising application of immune checkpoint inhibition.
4
19
Regulatory roles of IL-10–producing human follicular T cells jem.rupress.org/content/earl…
1
3
I'm a fan of testing early. Immune therapy more be more effective with less bulky disease.
Fascinating. Test early or late in the disease course? Seems like later could pick up more candidates for IO
2
7
Mary L. (Nora) Disis retweeted
Patient page on #CIPN (Chemo Induced Peripheral Neuropathy), in @JAMAOnc w/ @TimothyJBrownMD @ramsedhom #QOL matters. Can be photocopied non-commercially to share with patients. jamanetwork.com/journals/jam…
3
28
1
38
VERY IMPORTANT COMMENT!!! #ImmunoOnc19 @UWCancerVaccine
if presenters include NCT trial number 1) attendees can look at some of the perameters of trial (e.g. dosing) 2) clinicians can find out that this presentation of findings exist 3) if there is a related trial (or an open arm), patients can find out more about trial. #ImmunoOnc19
1
6
Dr. Kandalaft points out that there are many types of antigens that can be used for vaccination, neo antigens of all types- not just point mutations. Target epigenetic changes, phospho Ag...etc. #ImmunoOnc19 @UWCancerVaccine
Dr. Palucka highlights the importance of DC in mediating response to ICI. Recent Immunity paper implicated IFN-g and IL-12 in T cell DC cross-talk. https://nitter.cf/t.co/GMz0gUVuF4 #ImmunoOnc19 @UWCancerVaccine
1
2
4
Dendritic cells are the most important antigen presenting cells for stimulating T-cell responses to cancer. Nobel Prize winning tumor immunologist Dr. Ralph Steinman was honored for his work in this area. #ImmunoOnc19
1
15
Dr. Palucka highlights the issues associated with mutated antigen vaccines; the mutations have to be presented enodogenously in the patients MHC. Most are not. #Immunotherapy #immunoonc19 @UWCancerVaccine
3
11
Sounds exciting for endometrial cancer! #ImmunoOnc19
This quoted post is unavailable.
1
2
Surely there must be more data supporting a Phase III than just these 20 patients....!!!!#ImmunoOnc19
Phase II arm of lenvatinib + pembro in urothelial ca. n=20 pts. ORR 25% (5 objective responses + 7 decreased tumor size that didn't meet criteria). But, significant treatment related AE's frequent, including a fatal GI hemorrhage. Phase 3 coming- what do you think? #ImmunoOnc19
2
2
Many talks are associating PD-L1 tumor expression with clinical outcome- yet don't tell us definition of PD-L1 positivity. Is it 50%, 5%, 1%? On tumor? On immune "hot-spots"? on APC? Hard to figure out the utility of association. #ImmunoOnc19 @UWCancerVaccine
1
5